Crescent Biopharma, Inc.
General ticker "CBIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $313.4M (TTM average)
Crescent Biopharma, Inc. follows the US Stock Market performance with the rate: 37.2%.
Estimated limits based on current volatility of 4.0%: low 17.10$, high 18.52$
Factors to consider:
- Total employees count: 44 (-92.3%) as of 2025
- Top business risk factors: Limited operating history, No approved products, Clinical trial failure, Regulatory and compliance, Capital raising
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.74$, 20.80$]
- 2026-12-31 to 2027-12-31 estimated range: [4.59$, 15.07$]
Financial Metrics affecting the CBIO estimates:
- Negative: with PPE of -1.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -56.68 <= 0.28
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 84.49 > 63.63
- Positive: Interest expense per share per price, % of 1.73 <= 3.34
- Positive: Inventory ratio change, % of -27.71 <= -0.75
- Negative: Investing cash flow per share per price, % of -57.78 <= -14.39
Short-term CBIO quotes
Long-term CBIO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.01MM | $0.00MM | $10.84MM |
| Operating Expenses | $39.29MM | $40.04MM | $163.48MM |
| Operating Income | $-39.28MM | $-40.04MM | $-152.63MM |
| Non-Operating Income | $2.38MM | $2.16MM | $0.69MM |
| Interest Expense | $0.00MM | $0.85MM | $2.19MM |
| R&D Expense | $20.07MM | $28.06MM | $138.09MM |
| Income(Loss) | $-36.90MM | $-37.88MM | $-151.94MM |
| Taxes | $0.00MM | $0.00MM | $2.00MM |
| Net Income(Loss)* | $-36.90MM | $-37.88MM | $-153.94MM |
| Stockholders Equity | $38.41MM | $5.31MM | $203.01MM |
| Assets | $45.32MM | $11.09MM | $240.29MM |
| Operating Cash Flow | $-34.88MM | $-31.10MM | $-71.53MM |
| Capital expenditure | $0.02MM | $0.01MM | $72.92MM |
| Investing Cash Flow | $-0.02MM | $0.02MM | $-72.92MM |
| Financing Cash Flow | $28.82MM | $0.01MM | $322.98MM |
| Earnings Per Share** | $-58.25 | $-49.35 | $-14.78 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.